TransThera | 药捷安康 - Biotechnology, Life Sciences Company Profile, Funding Rounds and Investors

General Information

Company Name

TransThera | 药捷安康

Founded Year

2016

Location (Offices)

Founders / Decision Makers

Number of Employees

Industries

Biotechnology, Life Sciences

Funding Stage

Series D

Social Media

TransThera | 药捷安康 - Company Profile

TransThera | 药捷安康 is a clinical-stage biopharmaceutical company founded in 2016, aiming to address unmet medical needs by developing innovative therapeutics through an internal research platform and open innovation. Their diverse portfolio encompasses oncology, cardiovascular, and inflammatory diseases, demonstrating a commitment to transforming therapy and innovating for global patients. Having recently secured a significant CNY260.00M in Series D investment on 20 February 2023, TransThera attracted backing from prominent investors such as Trinity Innovation Fund and Honest Capital. With a focus on biotechnology and life sciences, TransThera is poised to make a substantial impact on the healthcare industry.

Taxonomy: biopharmaceutical, innovation, therapeutics, oncology, cardiovascular, inflammatory diseases, clinical-stage, research platform, open innovation, global patients, unmet medical needs, transformative therapy

Funding Rounds & Investors of TransThera | 药捷安康 (3)

View All

Funding Stage	Amount	No. Investors	Investors	Date
Series D	CNY260.00M	2	Honest Capital	20 Feb 2023
Series D	$100.00M	7	Co-Stone Venture Capital, China Merchants Venture Capital	25 Jul 2021
Series A	$10.00M	1		13 Oct 2016